reports
Prime Medicine Announces Additional Funding of Up to $24 Million from ...
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis -- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicine to receive up to $24 million in additional funding from the Cystic Fibrosis Foundation -- -- Multiple hotspot Prime Editors may benefit more than 93% of people with CF -- CAMBRIDGE, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed...
- David Nierengarten
- Dennis Pak
- Martin Fan
- Jonathan Moreland
GME GAMESTOP CORP. CLASS A
CEVA CEVA INC.
CDXS CODEXIS
OCSL OAKTREE SPECIALTY LENDING CORPORATION
FGBI FIRST GUARANTY BANCSHARES
KYMR KYMERA THERAPEUTICS
UWMC UWM HLDGS CORP
TRDA ENTRADA THERAPEUTICS INC
PRME PRIME MEDICINE INC
PMNT PERFECT MOMENT LTD.
RVYL RYVYL INC.
CCIF CARLYLE CREDIT INCOME FUND
- Jonathan Moreland
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
GLP GLOBAL PARTNERS LP
CDXS CODEXIS
BUSE FIRST BUSEY CORPORATION
AMPH AMPHASTAR PHARMACEUTICALS INC
OXM OXFORD INDUSTRIES INC.
PLYA PLAYA HOTELS & RESORTS
BCBP BCB BANCORP INC.
BRT BRT APARTMENTS
STKL SUNOPTA
SONO INC.
ENX SONOS
GRNT EATON VANCE NEW YORK MUNICIPAL BOND FUND
TCBX GRANIT SKOPKE
TYRA THIRD COAST BANCSHARES INC
BARK TYRA BIOSCIENCES INC
OPAL ORIGINAL BARK CO
PRME OPAL FUELS INC
GTE PRIME MEDICINE INC
SDHC GRAN TIERRA ENERGY INC.
NCDL SMITH DOUGLAS HOMES CORP
EVM NUVEEN CHURCHILL DIRECT LENDING CORP
EATON VANCE INSD CALIF MUN BD FD
- Jonathan Moreland
MTH MERITAGE HOMES CORPORATION
INUV INUVO INC
BHC BAUSCH HEALTH COMPANIES INC.
ETON ETON PHARMACEUTICALS
BLDR BUILDERS FIRSTSOURCE
AWRE INC.
DLHC AWARE INC.
HLMN DALEIGH HOLDINGS CORP
GECC HILLMAN SOLUTIONS CORP.
PRME GREAT ELM CAPITAL CORP
GTE PRIME MEDICINE INC
MNR GRAN TIERRA ENERGY INC.
EVM MACH NATURAL RESOURCES LP
EATON VANCE INSD CALIF MUN BD FD
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
TRS TRIMAS CORPORATION
TLYS TILLYS
PENN PENN NATIONAL GAMING INC.
PEB PEBBLEBROOK HOTEL TRUST
MCY MERCURY GENERAL CORPORATION
LTRX LANTRONIX INC.
JRVR JAMES RIVER GROUP HOLDINGS LTD
FLO FLOWERS FOODS INC.
BUSE FIRST BUSEY CORPORATION
VFF VILLAGE FARMS INTERNATIONAL IN
EXP EAGLE MATERIALS INC.
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
BDL FLANIGAN'S ENTERPRISES INC.
UIHC UNITED INSURANCE HOLDINGS CORP.
BXC BLUELINX HOLDINGS
HAIN THE HAIN CELESTIAL GROUP
GPMT INC.
NHF GRANITE POINT MORTGAGE TRUST INC.
BCBP NEXPOINT CREDIT STRATEGIES FUN
BRT BCB BANCORP INC.
PMTS BRT APARTMENTS
MPB CPI CARD GROUP
NWPP MID PENN BANCORP INC.
RFL NEW PEOPLES BANKSHARES INC.
KKR RAFAEL HOLDINGS CL B
REZI KKR & CO. INC.
LBSRD RESIDEO TECHNOLOGIES
XRX INC.
VLA LIBERTY STAR URANIUM & METALS
INNV XEROX HOLDINGS CORPORATION
ALIT ARBOR METALS
TCRX INNOVAGE HOLDING
UDMY ALIGHT
BHRB INC. / DELAWARE
OPAL FIRST EAGLE ALTERNATIVE CAPITAL BDC INC
PRME UDEMY INC
VFC BURKE & HERBERT BANK & TR/VA
UHG OPAL FUELS INC
HYLN PRIME MEDICINE INC
NCDL VF CORPORATION
PROP UNITED HOMES GROUP INC
FIP HYLIION HOLDINGS CORP.
TXO NUVEEN CHURCHILL DIRECT LENDING CORP
NEO PRAIRIE OPERATING CO.
JEQ FTAI INFRASTRUCTURE INC
MORNINGSTAR PARTNERS
L.P.
NEO CORPORATE PUBLIC COMPANY LIMITED
THE JAPAN EQUITY FUND
INC.
- Jonathan Moreland
SON SONOCO PRODUCTS COMPANY
NCR NCR CORPORATION
UNH UNITEDHEALTH GROUP INCORPORATED
RYAM RAYONIER ADVANCED MATERIALS INC
PLUG PLUG POWER INC.
PENN PENN NATIONAL GAMING INC.
PEB PEBBLEBROOK HOTEL TRUST
OEC ORION ENGINEERED CARBONS SA
MTX MINERALS TECHNOLOGIES INC.
MTDR MATADOR RESOURCES COMPANY
MO ALTRIA GROUP INC
LGND LIGAND PHARMACEUTICALS INCORPORATED
JRVR JAMES RIVER GROUP HOLDINGS LTD
HUN HUNTSMAN CORPORATION
HUM HUMANA INC.
ASB ASSOCIATED BANC-CORP
NEWT NEWTEK BUSINESS SERVICES INC.
RLMD RELMADA THERAPEUTICS
VFF VILLAGE FARMS INTERNATIONAL IN
HTLD HEARTLAND EXPRESS INC.
VSH VISHAY INTERTECHNOLOGY INC.
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
BXC BLUELINX HOLDINGS
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
CARS CARS.COM INC.
BRT BRT APARTMENTS
SNBR SLEEP NUMBER CORPORATION
MBIN MERCHANTS BANCORP
PMTS CPI CARD GROUP
LILA LIBERTY LATIN AMERICA A
COLD AMERICOLD REALTY TRUST
BBDC BARINGS BDC INC.
UTGN UTG
RPAY REPAY HOLDINGS (A)
XRX XEROX HOLDINGS CORPORATION
VLA ARBOR METALS
ONEW ONEWATER MARINE
MTCH MATCH GROUP INC.
PRG PROG HOLDINGS
MINM INC.
CIVI MINIM
UDMY INC.
OGN CIVITAS RESOURCES INC
OPAL UDEMY INC
PRME ORGANON & CO
VFC OPAL FUELS INC
PHIN PRIME MEDICINE INC
NCDL VF CORPORATION
FIP PHINIA INC
FG NUVEEN CHURCHILL DIRECT LENDING CORP
HCWB FTAI INFRASTRUCTURE INC
NEO F AND G ANNUITIES AND LIFE
INC.
HCW BIOLOGICS INC
NEO CORPORATE PUBLIC COMPANY LIMITED
Prime Medicine to Participate in Upcoming Investor Conferences
Prime Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Jefferies Global Healthcare Conference: Fireside chat on Thursday, June 5, 2025, at 10:30 a.m. ET in New York, NY.Goldman Sachs 46th Annual Global Healthcare Conference: Fireside chat on Monday, June 9, 2025, at 2:40 p.m. ET in Miam...
- Jonathan Moreland
TRS TRIMAS CORPORATION
PLUG PLUG POWER INC.
PENN PENN NATIONAL GAMING INC.
PEB PEBBLEBROOK HOTEL TRUST
MMLP MARTIN MIDSTREAM PARTNERS L.P.
JRVR JAMES RIVER GROUP HOLDINGS LTD
GLP GLOBAL PARTNERS LP
PATK PATRICK INDUSTRIES INC.
NEWT NEWTEK BUSINESS SERVICES INC.
RLMD RELMADA THERAPEUTICS
ELY CALLAWAY GOLF COMPANY
FLWS 1-800-FLOWERS.COM CL A
GBLI GLOBAL INDEMNITY PLC
SNDX SYNDAX PHARMACEUTICALS
HAIN THE HAIN CELESTIAL GROUP
NHF INC.
BRT NEXPOINT CREDIT STRATEGIES FUN
OCSL BRT APARTMENTS
MPB OAKTREE SPECIALTY LENDING CORPORATION
FGBI MID PENN BANCORP INC.
MIDD FIRST GUARANTY BANCSHARES
ENR THE MIDDLEBY CORPORATION
AVTR EDGEWELL PERSONAL CARE COMPANY
ZYME AVANTOR
VLA INC.
ONEW ZYMEWORKS INC.
ADV ARBOR METALS
DLHC ONEWATER MARINE
CVRX ADVANTAGE SOLUTIONS INC (A)
PFBX DALEIGH HOLDINGS CORP
TCRX CVRX
STGW INC.
OPAL PEOPLES FINANCIAL CORP. (MISSISSIPPI)
PRME FIRST EAGLE ALTERNATIVE CAPITAL BDC INC
STRW STAGWELL INC
PHIN OPAL FUELS INC
SRBK PRIME MEDICINE INC
SDHC STRAWBERRY FIELDS REIT INC.
FIP PHINIA INC
SUNS SR BANCORP INC
EVM SMITH DOUGLAS HOMES CORP
TXO FTAI INFRASTRUCTURE INC
GF SUNRISE REALTY TRUST
FG EATON VANCE INSD CALIF MUN BD FD
GREE MORNINGSTAR PARTNERS
HCWB L.P.
IAE THE NEW GERMANY FUND
FINS INC.
F AND G ANNUITIES AND LIFE
INC.
GREENIDGE GENERATION HLDGS INC
HCW BIOLOGICS INC
ING ASIA PACIFIC HIGH DIVIDEND EQUITY INCOME FUND
ANGEL OAK FINANCIAL STRATEGIES INCOME TERM TRUST
Prime Medicine Inc: 3 directors
Three Directors at Prime Medicine Inc bought/maiden bought 245,000 shares at between 1.130USD and 1.190USD. The significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's...
- Jonathan Moreland
LIND LINDBLAD EXPEDITIONS HOLDINGS
BXC BLUELINX HOLDINGS
GPMT GRANITE POINT MORTGAGE TRUST INC.
NHF NEXPOINT CREDIT STRATEGIES FUN
MPB MID PENN BANCORP INC.
NWPP NEW PEOPLES BANKSHARES INC.
BBDC BARINGS BDC INC.
MIDD THE MIDDLEBY CORPORATION
ENR EDGEWELL PERSONAL CARE COMPANY
AVTR AVANTOR
VLA INC.
HQL ARBOR METALS
ONEW TEKLA LIFE SCIENCES INVESTORS
ZIP ONEWATER MARINE
UDMY ZIPRECRUITER
OPAL INC.
PRME UDEMY INC
SDHC OPAL FUELS INC
FIP PRIME MEDICINE INC
EVM SMITH DOUGLAS HOMES CORP
GF FTAI INFRASTRUCTURE INC
FINS EATON VANCE INSD CALIF MUN BD FD
THE NEW GERMANY FUND
INC.
ANGEL OAK FINANCIAL STRATEGIES INCOME TERM TRUST
Prime Medicine Announces Strategic Restructuring to Focus on Opportuni...
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition -- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson’s Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Allan Reine, M.D., CFO, to succeed Keith Gottesdiener, M.D., as CEO; Jeff ...
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Rest...
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease -- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative -- -- Rapid engraftment observed in both neutrophils and platelets -- -- Encouraging safety profile; no serious adv...
- David Nierengarten
- Dennis Pak
- Martin Fan
Prime Medicine Reports First Quarter 2025 Financial Results and Provid...
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates -- Initial data from Phase 1/2 trial of PM359 for p47phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson’s Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 -- CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results f...
- David Nierengarten
- Dennis Pak
- Martin Fan
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
- David Nierengarten
- Dennis Pak
- Martin Fan
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsi...
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) -- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- -- High levels of editing at the target site in preclinical studies with full restoration of circulating wild-type AAT protein (M-AAT) to normal human range -- -- Expects to file IND and/or CTA in mid-2026 -- CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotech...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.